Latest News and Press Releases

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...

Dapirolizumab pegol (DZP) Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease activity/remission, flares, fatigue, joint pain and...

Belleville, Illinois, Sept. 05, 2025 (GLOBE NEWSWIRE) -- — Allsup, the nation’s premier disability representation company®, is proud to be a silver sponsor of the “2025 Walk To End Lupus Now, St....

EXTON, PA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights announces the upcoming release of its latest Special Topix™ service, Payer Management Strategies, providing pharmaceutical...

$3M NIH grant advances TRE-515, a first-in-class lupus therapy. Funding supports safety, biomarker studies, and paves the way for patient trials.

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Alumis Completes Patient Enrollment in Global LUMUS Phase 2b Trial of ESK-001, Next-Generation Oral TYK2 Inhibitor for SLE, data in 3Q 2026

Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Cutaneous Lupus Erythematosus Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035"...

Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activityDZP showed consistent improvements in fatigue,...

Alumis to present at Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 3:20 pm ET.